The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects

Prof. Dr. Steven Joniau is a Consultant Urologist at University Hospitals Leuven and a Scientific Secretary at Belgische Vereniging voor Urologie. He graduated with a degree in Urology in 2002 from the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Department of Urology, University Hospitals Leuven, after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven. His research interests are Medicine, Urology, Prostate Cancer, Urologic Oncology, Bladder Cancer, Kidney Cancer, Renal Cell Carcinoma, Urologic Neoplasms, General Surgery, Bladder Cancer, Emergency Medicine, Pediatrics, and Laparoscopic Surgery.

Prof. Dr. Gert De Meerleer is currently the head of clinics at the Department of Radiotherapy and Oncology at University Hospitals Leuven, Belgium. His field of interest is urologic oncology with a focus on implementing modern radiation technology in the treatment of prostate cancer, kidney cancer and, to a lesser extent, bladder cancer. He has pioneered the implementation of stereotactic body radiotherapy in the treatment of oligometastatic prostate cancer. This led to a paradigm shift in the treatment of these patients. He successfully defended his Ph.D. in 2000. Since then, he (co-)promoted several other Ph.D.s, most of them dealing with the implementation of intensity-modulated radiotherapy (including arc therapy) in the treatment of urological and, to a lesser extent, gynecologic malignancies. He has over 180 publications iso 135, most of them in the field of urological oncology and belonging to the highest quartile. He has received grants several times from different organizations (FWO, VLK, Stichting Tegen Kanker, etc.) for his scientific research. He is a full professor at Gent University and Leuven University. He is co-president of the Belgian Radiotherapy Awareness and Visibility Organization (BRAVO) and a board member of Scientific Summits. He has been invited as a speaker at most urologic and oncologic congresses.